Ovarian cancer had been the most difficult challenge in all gynecological tumors. Along with the ensemble medical technology stepping forward, the treatment of ovarian cancer was continuously improved. Traditional radical operation and postoperative chemotherapy was still nonattribute-based approaches in ovarian cancer; neoadjuvant chemotherapy (NAC) and preoperative interventional chemoembolization strived for operation opportunity for advanced ovarian cancer patients who had lost operation opportunity; intraperitoneal hyperthermic chemotherapy (IPHC) could safely and effectively postpone recidivation and improve the quality of life for advanced ovarian cancer patients; targeted therapy and immunotherapy were the major trend in prognosis for advanced ovarian cancer patients. This article was aimed to review the current situation of the therapies of middleadvanced ovarian cancer and provide references to enhance the survival rate and quality of life of middle-advanced ovarian cancer.